Lucinactant
Also known as: KL4 peptide surfactant, KL4 surfactant, lucinactant intratracheal suspension, Sinapultide, Surfaxin
Source Lucinactant at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Lucinactant (brand name Surfaxin) is a synthetic surfactant composed of the KL4 peptide and phospholipids, administered intratracheally to treat respiratory distress syndrome in preterm neonates.
Mechanism of Action
Mimics surfactant protein B; inserts into the alveolar surface to lower surface tension and improve lung compliance
Routes of Administration
Goals & Uses
- Treat neonatal respiratory distress syndromeTherapeuticHigh
- Prevention of Respiratory Distress Syndrome (RDS)Neonatal PulmonologyHigh
- Reduce need for mechanical ventilationClinical OutcomeModerate
- Improvement of lung compliance in premature infantsRespiratory SupportHigh
- Treatment of established RDSNeonatal PulmonologyModerate
- Aerosolized surfactant delivery (investigational)Drug Delivery InnovationLow
Contraindications
- Use in non-premature or term infants without surfactant deficiencyIndication MismatchModerate
- Known hypersensitivity to lucinactant or any componentAllergyHigh
- Pulmonary hemorrhageRespiratoryHigh
- Congenital airway malformationsStructuralModerate
Adverse Effects
- Endotracheal tube blockage or refluxProceduralUncommon
- Pulmonary edemaRespiratoryUncommon
- Oxygen desaturationPulmonaryCommon
- Pallor or cyanosisCardiovascular/RespiratoryCommon
- Pulmonary hemorrhagePulmonaryUncommon
- BradycardiaCardiovascularCommon
Drug Interactions
- Inhaled nitric oxideLow
Population Constraints
- Infants with active infection or sepsisConcurrent IllnessRelative
- Premature neonates (primary population)Age/developmentalAbsolute
- Preterm infants < 37 weeks gestational ageAge/gestationalAbsolute
- Infants with congenital anomalies affecting lung developmentStructural AnomalyRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization.
- United StatesWithdrawnApproved: Neonatal respiratory distress syndromeApproved 2012, marketing discontinued 2017.
- United KingdomUnapprovedNo marketing authorization.
FDA approved in 2012 for neonatal RDS; marketing discontinued in 2017; not approved in the EU or UK.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Lucinactant?
Lucinactant (brand name Surfaxin) is a synthetic surfactant composed of the KL4 peptide and phospholipids, administered intratracheally to treat respiratory distress syndrome in preterm neonates.
What is Lucinactant used for?
Lucinactant is educationally associated with: Treat neonatal respiratory distress syndrome, Prevention of Respiratory Distress Syndrome (RDS), Reduce need for mechanical ventilation, Improvement of lung compliance in premature infants, Treatment of established RDS, Aerosolized surfactant delivery (investigational). Educational only — not medical advice.
How is Lucinactant administered?
Recorded routes of administration: Endotracheal, Intratracheal.
What are the potential side effects of Lucinactant?
Reported adverse effects include: Endotracheal tube blockage or reflux, Pulmonary edema, Oxygen desaturation, Pallor or cyanosis, Pulmonary hemorrhage, Bradycardia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Lucinactant?
Recorded contraindications: Use in non-premature or term infants without surfactant deficiency, Known hypersensitivity to lucinactant or any component, Pulmonary hemorrhage, Congenital airway malformations. Consult a qualified clinician before use.